Exclusive: Immunotherapy developer Dynavax explores options for Hepatitis B drug-sources

Share this post

(Reuters) – Dynavax Technologies Corporation, a biotechnology company focused on drugs that harness the immune system to combat disease, is reviewing strategic options for its hepatitis B vaccine, which could include a potential sale or licensing deal, people familiar with the matter said.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply